ChannelAdvisor IPO ...
Health Care: Drugs
DepoMed Inc. (DEPO: NASDAQ)
$5.78 -0.01 | -0.17%
05/24/13 - 09:53 AM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 5.79 |
| 52 Week High | 7.15 |
| 52 Week Low | 4.91 |
| Avg. Daily Vol. (Mil) | 0.57 |
| Beta (3 year) | 1.16 |
| Share Related Items | |
| Mkt Cap (Mil) | 327.16 |
| Shares Out (Mil) | 56.50 |
| Float (Mil) | 56.09 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.50 |
| Current Ratio | 3.00 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 3.27 |
| Price/Book | 4.08 |
| Price/Cash Flow | -14.50 |
| Per Share Data | |
| Earnings | -0.47 |
| Sales | 1.77 |
| Book Value | 1.42 |
| Cash Flow | -0.40 |
| Business Summary | |
|---|---|
| DepoMed, Inc. is a specialty pharmaceutical company that focuses on pain and other conditions and diseases of the central nervous system. Its products line encompasses Gralise, Zipsor, Glumetza, Janumet XR, and Proquin XR, among others. | |
| General Information | |
| 7999 Gateway Boulevard
Suite 300 Newark, CA 94560 |
|
| www.depomedinc.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 155 | |
| CEO: James A. Schoeneck | |
| Short Interest | |
| Current Month (Mil) | 2.86 |
| Previous Month (Mil) | 2.80 |
| Short Interest Ratio (Days) | 6.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -19.60 |
| Return on Investments | -33.00 |
| Profitability | |
| Gross Margin | 93.90 |
| EBIT Margin | -26.50 |
| Profit Margin | -26.40 |
Portfolios with DEPO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorEarnings Short Squeeze Play...
- Usertracking
- UserAccelerant
- UserRASHID 1
- UserPortfolio 02
- UserJan Jan Portfolio 1
- Contributor10 Surging Stocks Most at R...
Latest DEPO Headlines from TheStreet
- Short Interest In DepoMed Moves 11% Lower 04.25.13 | 04:04 pm
- Top 10 Trending On StockTwits At The Close (March 4) 03.04.13 | 06:03 pm
- Depomed FDA Panel Live Blog 03.04.13 | 07:03 am
- Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta 03.01.13 | 06:03 am
- The Next Big Thing In Biotech: DepoMed
02.28.13 | 09:02 am - Depomed Inc. Stock Upgraded (DEPO) 02.22.13 | 04:02 am
- 5 Stocks Under $10 Triggering Breakouts 02.21.13 | 12:02 pm
- Depomed Bear Case: FDA Panel Will Ding Serada 02.04.13 | 08:02 am
- Stocks Under $5: Stealth Healthcare Play 12.19.12 | 11:12 am
- 2013 FDA Drug Approval Decision Calendar 12.19.12 | 09:12 am
Press Releases for DEPO
- Depomed To Present At UBS Global Healthcare Conference - PR Newswire 05.16.13 | 08:05 am
- Depomed To Report First Quarter Fiscal Year 2013 Financial Results On Wednesday, May 8, 2013 - PR Newswire 05.01.13 | 08:05 am
- Depomed To Present At Roth Capital Partners 25th Annual Growth Stock Conference - PR Newswire 03.13.13 | 04:03 pm
- Depomed Provides Update On SEFELSAâ¿¢ FDA Advisory Committee - PR Newswire 03.04.13 | 01:03 pm
- Trading Of Depomed Common Stock Halted - PR Newswire 03.04.13 | 07:03 am
- Depomed To Present At Cowen And Company Health Care Conference - PR Newswire 02.26.13 | 04:02 pm
- Depomed To Report Fourth Quarter Fiscal Year 2012 Financial Results On Wednesday, February 20, 2013 - PR Newswire 02.13.13 | 04:02 pm
- Depomed Announces Appointment Of Vicente J. Anido, Jr., Ph.D. To Board Of Directors, And Retirement Of Directors Julian N. Stern And Craig R. Smith, M.D. - PR Newswire 02.11.13 | 08:02 am
- EmergingGrowth.com Special Report On RVPlus, Inc., Oil And Gas, And Patents Infringement In Pharmaceuticals - PR Newswire 12.28.12 | 08:12 am
- Depomed Announces Dismissal Of Suit Against Two Gralise ANDA Filers Following Withdrawal Of ANDA And Patent Challenge - PR Newswire 12.26.12 | 04:12 pm
Partner Headlines for DEPO
- After Hours Most Active for May 20, 2013 : QQQ, SID, GGB, PBR, OZM, MSFT, APO, AAPL, BAC, RFMD, MYL, DEPO - NASDAQ 05.20.13 | 08:05 pm
- DepoMed Earnings: Everything You Must Know Now - Wall St. Cheat Sheet 05.08.13 | 06:05 am
- FDA Panel Kills Sefelsa, Creates Buying Opportunity In Depomed Stock - Seeking Alpha 03.05.13 | 09:03 am
- Roth Capital's Henry Sees Upcoming FDA Panel For Depomed's Sefelsa As A Coin Flip - Seeking Alpha 03.01.13 | 05:03 pm
- Serada Approval Presents Big Upside To Depomed - Seeking Alpha 01.30.13 | 09:01 am
- 5 Pharmaceutical Companies With Insider Buying During August 14-16 - Seeking Alpha 08.19.12 | 05:08 am
- Sell-Offs PROMPT Buying Opportunity for VF Corp. and 3 More Hot Analyst Alerts - Wall St. Cheat Sheet 06.21.12 | 03:06 am
- New Constructs' Most Attractive Stocks for June - Benzinga 06.04.12 | 09:06 am
- The Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Shire, Depomed, Comcast and Microsoft - Press Releases - Zacks 05.18.12 | 09:05 am
- Company News for February 7, 2012 - Corporate Summary - Zacks 02.07.12 | 10:02 am
